Alembic gets FDA OK for generic Optivar
Alembic Pharmaceuticals has received the Food and Drug Administration’s approval for azelastine hydrochloride ophthalmic solution, 0.05%.
The product is the generic of Mylan’s Optivar.
Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of
the eye associated with allergic conjunctivitis.
The product had a market value of roughly $8.5 million for the 12 months ended December 2018, according to IQVIA.
The product is the generic of Mylan’s Optivar.
Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of
the eye associated with allergic conjunctivitis.
The product had a market value of roughly $8.5 million for the 12 months ended December 2018, according to IQVIA.